Treatment outcomes of sofosbuvir/velpatasvir/voxilaprevir among NS5A inhibitor‐experienced patients with hepatitis C: Real‐world data from a multicenter Asian registry-Reference-Cited by-同舟云学术

Treatment outcomes of sofosbuvir/velpatasvir/voxilaprevir among NS5A inhibitor‐experienced patients with hepatitis C: Real‐world data from a multicenter Asian registry

Published:2022-06-30 Issue:8 Volume:37 Page:1642-1644
ISSN:0815-9319
Container-title:Journal of Gastroenterology and Hepatology
language:en
Short-container-title:J of Gastro and Hepatol

Author:

Wong YJ¹²^ORCID,Kumar R²³,Kumar R¹²^ORCID,Tan J¹²,Liu CH⁴,Hui VW‐K⁵,Tan SS⁶,Kao JH⁴^ORCID,Wong GL‐H⁵,Thurairajah PH⁷

Affiliation:

1. Changi General Hospital Changi Singapore

2. Duke‐NUS Medicine Academic Clinical Program, Singhealth Singapore

3. Singapore General Hospital Singapore

4. National Taiwan University Hospital Taipei Taiwan

5. Medical Data Analytics Centre The Chinese University of Hong Kong Hong Kong

6. Selayang Hospital Batu Caves Selangor Malaysia

7. National University Hospital Singapore

Funder

Duke-NUS Medical School

Publisher

Wiley

Subject

Gastroenterology,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jgh.15918

Reference14 articles.

1. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study

2. Sofosbuvir–velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial

3. Efficacy and safety of sofosbuvir/velpatasvir in a real‐world chronic hepatitis C genotype 3 cohort

4. American Association for the Study of Liver Diseases and Infectious Diseases Society of America.HCV guidance: recommendations for testing managing and treating hepatitis C. October 2021. Available at:www.hcvguidelines.org(accessed on 29 April 2022).

5. Vosevi.Prescribing information. Available online:www.gilead.com/~/media/files/pdfs/medicines/liver‐disease/vosevi/vosevi_pi.pdf(accessed on 29 April 2022).

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus Retreatment in Difficult-to-treat Patients: A Real-life Observational Study from India;Journal of Clinical and Experimental Hepatology;2024-03

2. Treatment Outcomes of Sofosbuvir/Velpatasvir/Voxilaprevir in Direct-Acting Antiviral-Experienced Hepatitis C Virus Patients: A Systematic Review and Meta-Analysis;Viruses;2023-06-30

3. Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan;Hepatology International;2023-01-26

4. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir retreatment in hepatitis C patients with different genotypes with DAAs failure in East China;2022-12-07

5. Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan;2022-11-09